Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma : a southwest oncology group trialMARGOLIN, K. A; LIU, P. Y; WEISS, G. R et al.Journal of cancer research and clinical oncology. 1999, Vol 125, Num 5, pp 292-296, issn 0171-5216Article

A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanomaFLAHERTY, L. E; REDMAN, B. G; CHALOT, G. G et al.Cancer. 1990, Vol 65, Num 11, pp 2471-2477, issn 0008-543X, 7 p.Article

Weekly 1-hour infusion of paclitaxel: Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinomaTRIVEDI, C; REDMAN, B; FLAHERTY, L. E et al.Cancer. 2000, Vol 89, Num 2, pp 431-436, issn 0008-543XArticle

Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma : a Southwest Oncology Group StudyMEYSKENS, F. L; KOPECKY, K. J; TAYLOR, C. W et al.Journal of the National Cancer Institute. 1995, Vol 87, Num 22, pp 1710-1713, issn 0027-8874Article

Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patientsCHABOT, G. G; FLAHERTY, L. E; VALDIVIESO, M et al.Cancer chemotherapy and pharmacology. 1990, Vol 27, Num 2, pp 157-160, issn 0344-5704, 4 p.Article

Metastatic melanoma from intraocular primary tumors: The Southwest Oncology Group experience in phase II advanced melanoma clinical trialsFLAHERTY, L. E; UNGER, J. M; LIU, P. Y et al.American journal of clinical oncology. 1998, Vol 21, Num 6, pp 568-572, issn 0277-3732Article

Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostatePIENTA, K. J; ESPER, P. S; ZWAS, F et al.American journal of clinical oncology. 1997, Vol 20, Num 1, pp 36-39, issn 0277-3732Article

The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma : A phase II trial of the Southwest Oncology Group (SWOG-8921)FLAHERTY, L. E; LIU, P. Y; MITCHELL, M. S et al.American journal of clinical oncology. 1996, Vol 19, Num 2, pp 108-113, issn 0277-3732Article

A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanomaWALLACK, M. K; MUTHUKUMARAN SIVANANDHAM; ROSEN, L et al.Cancer. 1995, Vol 75, Num 1, pp 34-42, issn 0008-543XArticle

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II Cytokine Working Group trialsFLAHERTY, L. E; ATKINS, M; SOROKIN, P et al.Journal of clinical oncology. 2001, Vol 19, Num 13, pp 3194-3202, issn 0732-183XArticle

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma : A southwest oncology group studyMARGOLIN, K. A; LIU, P.-Y; FLAHERTY, L. E et al.Journal of clinical oncology. 1998, Vol 16, Num 2, pp 664-669, issn 0732-183XArticle

A phase II trial of piroxantrone in disseminated malignant melanomaSOSMAN, J. A; FLAHERTY, L. E; LIU, P. Y et al.Investigational new drugs. 1995, Vol 13, Num 1, pp 83-87, issn 0167-6997Article

Inhibition of prostate cancer growth by estramustine and etoposidePIENTA, K. J; REDMAN, B. G; HUSSAIN, M et al.Cancer. 1995, Vol 75, Num 7, pp 1920-1926, issn 0008-543X, SUPConference Paper

Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanomaFLAHERTY, L. E; LIU, P. Y; UNGER, J et al.American journal of clinical oncology. 1997, Vol 20, Num 6, pp 600-604, issn 0277-3732Article

Oral etoposide in the treatment of hormone-refractory prostate cancerHUSSAIN, M. H; PIENTA, K. J; REDMAN, B. G et al.Cancer. 1994, Vol 74, Num 1, pp 100-103, issn 0008-543XArticle

Phase II trial of recombinant interleukin-1β in patients with metastatic renal cell carcinomaREDMAN, B. G; YOUSIF ABUBAKR; TA-HSU CHOU et al.Journal of immunotherapy. 1994, Vol 16, Num 3, pp 211-215, issn 1053-8550Conference Paper

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanomaFLAHERTY, L. E; ROBINSON, W; REDMAN, B. G et al.Cancer. 1993, Vol 71, Num 11, pp 3520-3525, issn 0008-543XArticle

Infection of T4 lymphocytes by HTLV-III does not require expression of the OKT4 epitopeHOXIE, J. A; FLAHERTY, L. E; HAGGARTY, B. S et al.The Journal of immunology (1950). 1986, Vol 136, Num 2, pp 361-363, issn 0022-1767Article

Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: Pathologic corollary of Eastern Cooperative Oncology Group Trial E1690RAO, U. N. M; IBRAHIM, J; FLAHERTY, L. E et al.Journal of clinical oncology. 2002, Vol 20, Num 8, pp 2053-2057, issn 0732-183XArticle

High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190KIRKWOOD, J. M; IBRAHIM, J. G; SONDAK, V. K et al.Journal of clinical oncology. 2000, Vol 18, Num 12, pp 2444-2458, issn 0732-183XArticle

A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancerSMITH, D. C; REDMAN, B. G; FLAHERTY, L. E et al.Urology (Ridgewood, NJ). 1998, Vol 52, Num 2, pp 257-260, issn 0090-4295Article

A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostatePIENTA, K. J; REDMAN, B. G; ESPER, P. S et al.American journal of clinical oncology. 1996, Vol 19, Num 5, pp 500-503, issn 0277-3732Article

Evaluation of merbarone (NSC 336628) in disseminated malignant melanomaSLAVIK, M; LIU, P. Y; KRAUT, E. H et al.Investigational new drugs. 1995, Vol 13, Num 2, pp 143-147, issn 0167-6997Article

Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma : phase II southwest oncology group trialFLAHERTY, L. E; LIU, P. Y; FLETCHER, W. S et al.Journal of the National Cancer Institute. 1992, Vol 84, Num 11, pp 893-894, issn 0027-8874Article